Midwest providers eye new financial opportunities
Related Articles
Anumana’s ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm.…May 23, 2022
Anumana Expands AI Platform from Diagnostic Solutions to the Full Continuum of Cardiovascular Care
New investment fuels growth of ECG-AI platform and development of perioperative AI capabilitiesApril 24, 2025
Anumana Announces Issuance of New American Medical Association CPT® Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithmsJuly 05, 2022
FDA grants breakthrough designation for Anumana’s ECG-AI algorithm
Medical Device Network: The US Food and Drug Administration (FDA) has granted breakthrough device designation (BDD) for the electrocardiogram-artificial intelligence (ECG-AI) algorithm by AI-driven health technology company Anumana. The algorithm…June 22, 2023